Growth Metrics

Merck (MRK) Cash from Financing Activities (2016 - 2025)

Merck (MRK) has disclosed Cash from Financing Activities for 17 consecutive years, with $4.8 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 257.89% to $4.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.9 billion, a 72.67% increase, with the full-year FY2025 number at -$1.9 billion, up 72.67% from a year prior.
  • Cash from Financing Activities was $4.8 billion for Q4 2025 at Merck, up from $2.6 billion in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $5.2 billion in Q4 2021 to a low of -$5.8 billion in Q1 2025.
  • A 5-year average of -$989.3 million and a median of -$2.2 billion in 2021 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 311.48% in 2023, then tumbled 392.43% in 2025.
  • Merck's Cash from Financing Activities stood at $5.2 billion in 2021, then plummeted by 129.84% to -$1.6 billion in 2022, then crashed by 44.47% to -$2.2 billion in 2023, then crashed by 34.03% to -$3.0 billion in 2024, then soared by 257.89% to $4.8 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Cash from Financing Activities are $4.8 billion (Q4 2025), $2.6 billion (Q3 2025), and -$3.6 billion (Q2 2025).